Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Neuro-oncology - 1 Jun 2013

Juratli Tareq A, Peitzsch Mirko, Geiger Kathrin, Schackert Gabriele, Eisenhofer Graeme, Krex Dietmar

Abstract excerpt

OBJECTIVES: To determine whether accumulation of 2-hydroxyglutarate in IDH-mutated low-grade gliomas (LGG; WHO grade II) correlates with their malignant transformation and to evaluate changes in metabolite levels during malignant progression. METHODS: Samples from 54 patients were screened for IDH mutations: 17 patients with LGG without malignant transformation, 18 patients with both LGG and their consecutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Survival Rate

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 23410661
DOI: 10.1093/neuonc/not006
PMCID: PMC3661092

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.PMID 23410661Read ↗

Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.Semantic proximity Read ↗

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.Semantic proximity Read ↗

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.Semantic proximity Read ↗

Metabolism of glioma and IDH1/IDH2 mutations.Semantic proximity Read ↗

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.Semantic proximity Read ↗

Quantitative analysis of 2-hydroxyglutarate as a controversial oncometabolite in malignant gliomas.Semantic proximity Read ↗

Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Semantic proximity Read ↗

2-Hydroxyglutarate in Cancer Cells.Semantic proximity Read ↗

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.Semantic proximity Read ↗

Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry.Semantic proximity Read ↗

D-2-Hydroxyglutarate in Glioma Biology.Semantic proximity Read ↗

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.